米国市場銘柄情報

ADVM アドベラム・バイオテクノロジーズ

銘柄追加

10.4300
+0.4300+4.30%

終値 05/03 16:00 ET

10.2500
-0.1800-1.73%

市場後 17:42 ET

2.16億時価総額-899直近PER

アドベラム・バイオテクノロジーズに関するコメント

ログインコメントを投稿

Trytosaveabit

02/08 20:05

Update

$アドベラム・バイオテクノロジーズ(ADVM.US)$ Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...

QianmengYu

02/06 04:44

Sold half at 1.8 but chart look good

$アドベラム・バイオテクノロジーズ(ADVM.US)$ 2 insiders buy 200k cash in private placement, settlement Feb 8 the data release day. Lol, simple insider trading. Are they stupid? Anyway, there won’t be surprise for the data release, should be safe pass.
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...

BadDuck74

02/05 21:38

$アドベラム・バイオテクノロジーズ(ADVM.US)$Adverum Biotechnologies Has Agreed To Sell Approximately 106.25M Shares In A Private Placement At $1.20/Share With Gross Proceeds Of Approximately $127.5M; Pro Forma Cash And Investments Expected To Fund Current Operating Plan Into Late 2025

QianmengYu

02/02 22:51

feels like insider action.

$アドベラム・バイオテクノロジーズ(ADVM.US)$ I’ll probably sell most position at $2. I feels like phase 2 is great, and they are working with some IB to do stock offering once news is out.

Moomoo AI

01/29 21:14

Dr. Corbau's appointment, with his gene therapy expertise, is seen as crucial for Adverum's Ixo-vec advancement towards pivotal trials and commercialization for treating wet AMD. He is eager to progress Adverum's early-stage research assets and sees Ixo-vec as a potential leading therapy for wet AMD.

Press Release: Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer

Meltyy

01/24 17:25

Ph2 readouts in Q1 2024...

$ファイザー(PFE.US)$ Phase 2
$リープ・セラピューティクス(LPTX.US)$ Phase 2
$ヴェラ・セラピューティクス(VERA.US)$ Phase 2b
$4Dモレキュラー・セラピューティクス(FDMT.US)$ Phase 2
$アドベラム・バイオテクノロジーズ(ADVM.US)$ Phase 2
$デナリ・セラピューティクス(DNLI.US)$ Phase 2
$アケロ･セラピューティクス(AKRO.US)$ Phase 2b
$スプルース・バイオサイエンシズ(SPRB.US)$ Phase 2
$ゼンコー(XNCR.US)$ Phase 2
$アルナイラム・ファーマシューティカルズ(ALNY.US)$ Phase 2
$ハーモニー・バイオサイエンシーズ(HRMY.US)$ Phase 2
$アネクソン(ANNX.US)$ Phase 2a
$ロイバント・サイエンシズ(ROIV.US)$...

Trytosaveabit

01/19 03:57

Was taking this bit of Grrr time in market to look at some notes. Found this and ima share. Hehehe

$アドベラム・バイオテクノロジーズ(ADVM.US)$ Seems DATA date is coming on 2/8/24? May be time if you dont have a position that your making a bit of profit from? To be looking for a ST? Or make yourself a note/reminder. Just thinking outloud! Hehehe

Screenshot of my note to help you make a note! Use your tools available to make you a successful trader

Meltyy

01/03 20:11

Upcoming Ph 2 readouts in Q1 2024…

$セレクタ・バイオサイエンシズ(CLRB.US)$ Phase 2
$リジェネックスバイオ(RGNX.US)$ Phase 2
$リープ・セラピューティクス(LPTX.US)$ Phase 2
$4Dモレキュラー・セラピューティクス(FDMT.US)$ Phase 2
$アドベラム・バイオテクノロジーズ(ADVM.US)$ Phase 2
$デナリ・セラピューティクス(DNLI.US)$ Phase 2
$アイポイント・ファーマシューティカルズ(EYPT.US)$ Phase 2
$ゼンコー(XNCR.US)$ Phase 2
$ハーモニー・バイオサイエンシーズ(HRMY.US)$ Phase 2
$アルナイラム・ファーマシューティカルズ(ALNY.US)$ Phase 2
$ディスク・メディシン(IRON.US)$ Phase 2
$アテア・ファーマシューティカルズ(AVIR.US)$ Phase 2
$アラコス(ALLK.US)$ Phase 2...

Trytosaveabit

2023/11/05 17:08

New!

$アドベラム・バイオテクノロジーズ(ADVM.US)$ Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients With Wet AMD at AAO 2023
- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction in anti-VEGF treatment burden -
- 84% reduction in annualized anti-VEGF injections, with 53% of the participants at the 2E11 ...

Trytosaveabit

2023/09/27 04:08

UPDATE!

$アドベラム・バイオテクノロジーズ(ADVM.US)$ Adverum Biotechnologies Reports Aflibercept Protein Level Data From LUNA Phase 2 Trial; Says Ixo-vec Has Been Well Tolerated With Favorable Preliminary Safety Profile

まだコメントはありません

分析

アナリスト評価

データなし

目標株価

データなし

ホット

米国株

総合人気